Want to see SE:APOTEA full AI Analyst Report?
Top Page
Apotea AB
(APOTEA)
Select Model
Select Model
Rating:58Neutral
Price Target:
kr94.00
▲(24.83% Upside)
Action:Reiterated
Date:10/18/26
The score is held back primarily by cash-flow softness and a demanding valuation (high P/E with low yield). Financial performance is improving with better profitability and manageable leverage, but thin margins and weaker recent free-cash-flow conversion limit confidence. Technically, the trend is strong, yet overbought readings raise near-term risk.
Positive Factors
Revenue growth
Revenue has continued to expand, with TTM revenue up approximately 2.7% and the reported revenue-growth measure at 9.35%. Continued top-line gains indicate ongoing customer demand and provide a foundation for scale benefits over the next several quarters.
Negative Factors
Weaker cash conversion
Although free cash flow remains positive, its approximately 31.8% decline and coverage of only about 0.69 times TTM net income show weaker conversion into cash. This can constrain reinvestment flexibility and makes durable earnings quality more dependent on improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth
Revenue has continued to expand, with TTM revenue up approximately 2.7% and the reported revenue-growth measure at 9.35%. Continued top-line gains indicate ongoing customer demand and provide a foundation for scale benefits over the next several quarters.
Read all positive factors
Apotea AB (APOTEA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr9.53B
Dividend Yield0.66%
Average Volume (3M)244.97K
Price to Earnings (P/E)38.8
Beta (1Y)0.43
Revenue Growth9.35%
EPS Growth-91.93%
CountrySE
Employees736
SectorGeneral
Sector StrengthN/A
IndustrySpecialty Retail
Share Statistics
EPS (TTM)2.36
Shares Outstanding104,070,970
10 Day Avg. Volume281,985
30 Day Avg. Volume244,969
Financial Highlights & Ratios
PEG Ratio7.96
Price to Book (P/B)11.37
Price to Sales (P/S)1.33
P/FCF Ratio81.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.81
Revenue Forecast (FY)kr8.07B
Apotea AB Business Overview & Revenue Model
Company Description
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, ha...
How the Company Makes Money
Apotea makes money primarily by selling products directly to consumers via its online channels. Key revenue streams include: (1) Prescription medicines: revenue from dispensing prescription drugs ordered through Sweden’s e-prescription system and ...
Apotea AB Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
69
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.59B | 7.20B | 6.54B | 5.45B | 4.88B | 4.56B |
| Gross Profit | 1.93B | 1.94B | 1.79B | 1.45B | 1.27B | 750.33M |
| EBITDA | 518.81M | 464.10M | 399.60M | 226.00M | 104.80M | 183.77M |
| Net Income | 245.60M | 228.70M | 214.90M | 87.00M | 19.90M | 104.49M |
Balance Sheet | ||||||
| Total Assets | 2.23B | 1.98B | 146.49M | 132.18M | 1.25B | 1.02B |
| Cash, Cash Equivalents and Short-Term Investments | 103.50M | 3.31M | 2.46M | 1.89M | 18.20M | 81.38M |
| Total Debt | 279.30M | 331.00M | 21.78M | 25.89M | 332.70M | 144.33M |
| Total Liabilities | 1.26B | 1.12B | 89.25M | 90.14M | 897.50M | 684.99M |
| Stockholders Equity | 947.00M | 844.00M | 55.37M | 39.93M | 327.50M | 339.76M |
Cash Flow | ||||||
| Free Cash Flow | 152.00M | 117.70M | 42.40M | 94.70M | -110.60M | 145.82M |
| Operating Cash Flow | 234.01M | 333.30M | 206.20M | 215.80M | 31.50M | 227.30M |
| Investing Cash Flow | -82.20M | -214.50M | -163.70M | -121.60M | -141.40M | -81.58M |
| Financing Cash Flow | -117.50M | -115.30M | -34.20M | -93.30M | 46.30M | -78.39M |
Apotea AB Technical Analysis
Positive
75.30
Price Trends
81.12
Positive
77.79
Positive
71.83
Positive
Market Momentum
2.93
Negative
73.34
Negative
89.79
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:APOTEA, the sentiment is Positive. The current price of 75.3 is below the 20-day moving average (MA) of 86.80, below the 50-day MA of 81.12, and above the 200-day MA of 71.83, indicating a bullish trend. The MACD of 2.93 indicates Negative momentum. The RSI at 73.34 is Negative, neither overbought nor oversold. The STOCH value of 89.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:APOTEA.
Apotea AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | kr31.08B | 24.61 | 41.64% | 2.91% | 9.82% | 33.55% | |
61 Neutral | kr12.47B | 21.05 | ― | 2.22% | 8.20% | 40.01% | |
58 Neutral | kr9.53B | 38.79 | ― | 0.66% | 9.35% | -91.93% | |
56 Neutral | kr112.42M | -47.71 | -2.54% | ― | -8.90% | 67.39% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | kr523.58M | -8.14 | ― | ― | 7.12% | 8.47% | |
52 Neutral | kr1.82B | -52.49 | -2.25% | ― | -2.34% | 93.68% |
* General Sector Average
SE:APOTEA
Apotea AB
91.55
4.41
5.06%
SE:CLAS.B
Clas Ohlson AB
489.00
145.68
42.43%
SE:DSNO
Desenio Group AB
0.11
0.04
46.15%
SE:KJELL
Kjell Group AB
19.10
10.98
135.19%
SE:RUSTA
Rusta AB
81.25
19.23
31.00%
SE:CDON
CDON AB
46.50
-13.70
-22.76%
Apotea AB Corporate Events
Apotea Sets Date for Q3 2026 Report and Investor Webcast
Oct 9, 2026
Apotea AB will publish its third-quarter 2026 report on 5 November at 07:30 CEST and follow up with a webcast presentation at 09:30 CEST the same day. The interim results for January to September 2026 will be presented in English by CEO Pär S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.